The HCPLive Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.
May 11th 2024
As disparate representation in pivotal research impacts the outcomes of common diseases like lupus, clinicians and researchers alike are working to foster trust and collaboration with more patients of color.
New Promising Phase 3 Bimekizumab Data Among Patients with Psoriatic Arthritis
May 23rd 2022Data from 2 studies evaluating adults with active psoriatic arthritis were announced today in preparation for EULAR 2022. The different population groups who received treatment were biologic-naive patients and TNF-inadequate responders.
Secukinumab Receives Positive CHMP Opinion for Expansion in Childhood Arthritic Conditions
The Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion to expand Novartis secukinumab indication to enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA).
Julie J Paik, MD, MHS: Inflammatory Myopathy in Systemic Rheumatic Diseases
Julie J Paik, MD, MHS, discusses the clinicoserological spectrum of inflammatory myopathy in the context of rheumatic diseases and how autoantibody profiles can help predict myositis phenotype and disease course.
Lupus Nephritis: TULIP-LN Hints at a Blossoming Role for Anifrolumab
May 10th 2022In the double blinded study, patients were randomized to receive anifrolumab (300mg monthly), an intensified regimen of 3 x 900mg doses followed by 300mg monthly, or standard of care therapy with mycophenolate mofetil and oral glucocorticoids.
From Living BLISSfully to BEATing Lupus: Future Considerations for Biologic Therapy in SLE
May 9th 2022After years of frustration and failure, trials of targeted biologic therapy in systemic lupus erythematosus are beginning to show success. New drugs, including anifrolumab (Saphnelo) and belimumab (Benlysta), are paving the way for an exciting new era. However, this raises new questions as to how these novel therapeutics will be incorporated into future clinical practice.